Description
ADCC-Enhanced anti-Semaphorin 4A (HuLB70) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Autoimmune Disease; Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Semaphorin 4A antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
SEMA4A
Full Name
sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4A
Background
This gene encodes a member of the semaphorin family of soluble and transmembrane proteins. Semaphorins are involved in numerous functions, including axon guidance, morphogenesis, carcinogenesis, and immunomodulation. The encoded protein is a single-pass type I membrane protein containing an immunoglobulin-like C2-type domain, a PSI domain and a sema domain. It inhibits axonal extension by providing local signals to specify territories inaccessible for growing axons. It is an activator of T-cell-mediated immunity and suppresses vascular endothelial growth factor (VEGF)-mediated endothelial cell migration and proliferation in vitro and angiogenesis in vivo. Mutations in this gene are associated with retinal degenerative diseases including retinitis pigmentosa type 35 (RP35) and cone-rod dystrophy type 10 (CORD10). Multiple alternatively spliced transcript variants encoding different isoforms have been identified.
Alternative Names
SEMA4A; sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4A; RP35; SEMB; SEMAB; CORD10; semaphorin-4A; sema B; semaphorin-B
Gene ID
64218
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with SEMA4A include Retinitis Pigmentosa 35 and Cone-Rod Dystrophy 10.
Related Pathways
Its related pathways are Axon guidance and Developmental Biology.
Function
PLXNB1, PLXNB2, PLXNB3 and PLXND1 are cell surface receptors that play an important role in cell-cell signaling (similarity). Regulates the development of glutamatergic and GABAergic synapses (through similarity). Promote the development of inhibitory synapses in a plxnb1-dependent manner, and promote the development of excitatory synapses (through similarity) in a plxnb2-dependent manner. Activate antigen-specific t cells to promote Th1 t helper cell differentiation, thereby promoting adaptive immunity (through similarity). Promote the phosphorylation of TIMD2 (through similarity). Inhibit angiogenesis (through similarity). Promote axonal growth cone collapse (similar). By providing a local signal to specify the area that the growing axon cannot reach (through similarity), the axon expansion is inhibited.
Post-translational modifications
1.Glycosylation at Asn120, Asn135, Asn496, and Asn607 2.Modification sites at PhosphoSitePlus 3.Ubiquitination at Lys219 and Lys535
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
HuLB70
Description
The anti-human sema4A antibody are useful in treating autoimmune diseases, cancers and other disease. Anti-human sema4A antibody can inhibit T cell proliferation and Th2 differentiation induced by IL-4, anti-CD3, anti-CD28 and recombinant sema4A.
Antibody Indication
Autoimmune Disease; Cancer
Autoimmune Disease; Cancer
